Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 70518-4680

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 70518-4680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Description: Clopidogrel 75 mg tablets in a quantity of 30. The tablets are round and pink in color. The product has been repackaged by RemedyRepack Inc. and the manufacturing information indicates Dr. Reddy's Labs in Princeton, New Jersey. The usual dosage information should be referred to the insert provided. The medication should be kept out of reach of children and stored at a temperature of 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines.*

FDA Label Image

Figure1 (Figure1)

This text provides information on the effect of co-administered proton pump inhibitors (PPIs) on the area under the curve (AUC) of an active metabolite. It includes the mean and 90% confidence interval for different PPI drugs such as Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole at varying doses. The data shown is likely part of a study or research comparing the impact of different PPIs on the active metabolite AUC.*

FDA Label Image

Figure2 (Figure2)

This is a comparison of the event rates between two treatments, one being Placebo with aspirin and the other being Clopidogrel with aspirin. The cumulative event rates are shown over the course of several months of follow-up. Other standard therapies were also utilized alongside these treatments.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text provides information on the comparison between a placebo and Clopidogrel in terms of the number of deaths recorded. It states that there were 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the Clopidogrel group, showing a 0.6% difference in death rates. Additionally, it mentions a 7% proportional risk reduction with Clopidogrel compared to the placebo, with a p-value of 0.03. The data seems to be related to observations over a period of up to 28 days after randomization.*

FDA Label Image

Figure5 (Figure5)

This text appears to be a statistic related to a study or clinical trial comparing the outcomes of patients treated with a placebo versus those treated with clopidogrel. The results show that 2310 patients experienced an event (10.1%) in the placebo group, while 2121 patients experienced an event (92%) in the clopidogrel group. The study also suggests a 9% proportional risk reduction (p=0.002) with clopidogrel treatment. The events mentioned could be related to death, reinfarction, or stroke within a certain period specified as "Days since randomization (up to 28 days)."*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.